Identifying patient preferences for communicating risk estimates: A descriptive pilot study
Reads0
Chats0
TLDR
Although there are many different formats for presenting and framing risk information, simple bar charts depicting absolute lifetime risk were rated and ranked highest overall for patient preferences for format.Abstract:
Patients increasingly seek more active involvement in health care decisions, but little is known about how to communicate complex risk information to patients. The objective of this study was to elicit patient preferences for the presentation and framing of complex risk information. To accomplish this, eight focus group discussions and 15 one-on-one interviews were conducted, where women were presented with risk data in a variety of different graphical formats, metrics, and time horizons. Risk data were based on a hypothetical woman's risk for coronary heart disease, hip fracture, and breast cancer, with and without hormone replacement therapy. Participants' preferences were assessed using likert scales, ranking, and abstractions of focus group discussions. Forty peri- and postmenopausal women were recruited through hospital fliers (n = 25) and a community health fair (n = 15). Mean age was 51 years, 50% were non-Caucasian, and all had completed high school. Bar graphs were preferred by 83% of participants over line graphs, thermometer graphs, 100 representative faces, and survival curves. Lifetime risk estimates were preferred over 10 or 20-year horizons, and absolute risks were preferred over relative risks and number needed to treat. Although there are many different formats for presenting and framing risk information, simple bar charts depicting absolute lifetime risk were rated and ranked highest overall for patient preferences for format.read more
Citations
More filters
Journal ArticleDOI
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.
Ramachandran S. Vasan,Alexa S. Beiser,Sudha Seshadri,Sudha Seshadri,Martin G. Larson,Martin G. Larson,William B. Kannel,William B. Kannel,Ralph B. D'Agostino,Daniel Levy,Daniel Levy,Daniel Levy +11 more
TL;DR: The residual lifetime risk for hypertension for middle-aged and elderly individuals is 90%, indicating a huge public health burden, and efforts should be directed at the primary prevention of hypertension.
Journal ArticleDOI
The Lifetime Risk of Stroke Estimates From the Framingham Study
Sudha Seshadri,Alexa S. Beiser,Margaret Kelly-Hayes,Carlos S. Kase,Rhoda Au,William B. Kannel,Philip A. Wolf +6 more
TL;DR: The lifetime risk of stroke in middle-aged adults is 1 in 6 or more, which is equal to or greater than the LTR of AD, and women had a higher risk because of longer life expectancy.
Journal ArticleDOI
Explaining risks: turning numerical data into meaningful pictures
TL;DR: Whether the shift towards a greater use of information in consultations is helpful and how information can be used without losing the benefits that are traditionally associated with the art, rather than the science, of medicine are explored.
Journal ArticleDOI
The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study
L E Bayliss,David Culliford,A Paul Monk,Sion Glyn-Jones,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra,Daniel Prieto-Alhambra,Andrew Judge,Andrew Judge,Cyrus Cooper,Cyrus Cooper,Andrew Carr,Nigel K Arden,Nigel K Arden,David J Beard,Andrew Price +15 more
TL;DR: The evidence challenges the increasing trend for more total hip replacements and total knee replacements to be done in the younger patient group, and these data should be offered to patients as part of the shared decision making process.
Journal ArticleDOI
Design Features of Graphs in Health Risk Communication: A Systematic Review
TL;DR: Communicators should not assume that all graphics are more intuitive than text; many of the studies found that patients' interpretations of the graphics were dependent upon expertise or instruction and successful ways to communicate uncertainty about risk are needed.
References
More filters
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Journal ArticleDOI
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Deborah Grady,Susan M. Rubin,Diana B. Petitti,Cary Fox,Dennis M. Black,Bruce Ettinger,Virginia L. Ernster,Steven R. Cummings +7 more
TL;DR: To critically review the risks and benefits of hormone therapy for asymptomatic postmenopausal women who are considering long-term hormone therapy to prevent disease or to prolong life-long hormone therapy is critically reviewed.
Journal ArticleDOI
The number needed to treat: a clinically useful measure of treatment effect.
Richard J. Cook,David L. Sackett +1 more
TL;DR: The relative benefit of an active treatment over a control is usually expressed as the relative risk, the Relative risk reduction, or the odds ratio, but for clinical decision making, it is more meaningful to use the measure "number needed to treat."
Journal ArticleDOI
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Graham A. Colditz,Susan E. Hankinson,David J. Hunter,Walter C. Willett,JoAnn E. Manson,Meir J. Stampfer,Charles H. Hennekens,Bernard Rosner,Frank E. Speizer +8 more
TL;DR: In this paper, the effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is investigated. But, the effect on the number of newly diagnosed invasive breast cancer cases was not quantified.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.